FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.
What happened
FDA inspected Macsen Drugs from September 2 to 6, 2024. FDA found that the quality unit released active pharmaceutical ingredient (API) lots it had identified as impacted by a December 2022 fire for U.S. distribution, and that stability chambers had power failures of up to 40 hours without data loggers or data showing API quality through expiry. FDA reviewed the firm’s September 27, 2024 response and called it inadequate.
What FDA found
The quality unit (the group responsible for release decisions) released API lots that its incident report identified as impacted by a December 2022 fire for U.S. distribution.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The quality unit did not ensure stability data supported API retest or expiry dates and storage conditions.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells Macsen to respond in writing within 15 working days with what it has done to correct the deviations and prevent recurrence; if it cannot complete actions, it must explain delays and give a schedule. FDA also asks for a comprehensive quality-unit remediation plan, an independent stability-program assessment and corrective action plan, and an action plan for affected U.S. API lots, including customer notifications and recalls.
Who should pay attention
- drugmakers that use Macsen APIs in U.S. products
- brands and contractors sourcing APIs from this facility
- quality teams managing supplier qualification and recalls
This is a summary. Read the original letter on fda.gov.